DexCom, Inc. $DXCM Shares Purchased by Geneva Capital Management LLC

Geneva Capital Management LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 14.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 149,856 shares of the medical device company’s stock after purchasing an additional 18,773 shares during the quarter. Geneva Capital Management LLC’s holdings in DexCom were worth $12,931,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Latitude Advisors LLC purchased a new position in DexCom in the third quarter valued at about $32,000. Hilton Head Capital Partners LLC raised its holdings in DexCom by 242.3% in the third quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock worth $33,000 after purchasing an additional 269 shares in the last quarter. Wellington Grp LLC raised its holdings in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares in the last quarter. Elevation Wealth Partners LLC raised its holdings in DexCom by 61.0% in the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after purchasing an additional 152 shares in the last quarter. Finally, GK Wealth Management LLC purchased a new stake in shares of DexCom during the third quarter valued at about $35,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a $105.00 price target (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Citigroup lifted their price objective on shares of DexCom from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Wells Fargo & Company boosted their price objective on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Leerink Partners decreased their target price on shares of DexCom from $94.00 to $87.00 and set an “outperform” rating for the company in a research report on Monday, October 26th. Finally, Sanford C. Bernstein increased their target price on shares of DexCom from $77.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $95.50.

Check Out Our Latest Stock Report on DexCom

Insider Buying and Selling at DexCom

In other DexCom news, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the completion of the transaction, the director owned 29,293 shares in the company, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total value of $201,660.30. Following the transaction, the executive vice president owned 120,913 shares of the company’s stock, valued at $9,506,180.06. The trade was a 2.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,822 shares of company stock worth $1,920,193 over the last ninety days. 0.28% of the stock is owned by insiders.

DexCom Stock Performance

DXCM opened at $83.33 on Monday. DexCom, Inc. has a 12-month low of $56.72 and a 12-month high of $92.59. The company has a current ratio of 1.74, a quick ratio of 1.40 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $31.08 billion, a PE ratio of 32.68, a P/E/G ratio of 1.38 and a beta of 1.45. The firm has a 50 day moving average of $84.30 and a two-hundred day moving average of $75.21.

DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.61 EPS. On average, analysts anticipate that DexCom, Inc. will post 2.68 EPS for the current year.

DexCom Company Profile

(Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Featured Articles

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.